DDrare: Database of Drug Development for Rare Diseases

Linoleic acid (DrugBank: Linoleic acid)

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
299	Cystic fibrosis	1

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00638196 (ClinicalTrials.gov)	March 2008	10/3/2008	Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS	Phase II Study of Linoleic Acid in Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Linoleic Acid/Oleic Acid	University of Rochester	NULL	Terminated	18 Years	70 Years	Both	9	Phase 1	United States

299. Cystic fibrosis [ 1,592 clinical trials, 1,539 drugs, (DrugBank: 255 drugs), 81 drug target genes, 162 drug target pathways]

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 1,592 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04531410 (ClinicalTrials.gov)	September 1, 2020	18/8/2020	NETwork of Linoleic Acid Supplementation in Cystic Fibrosis	Double-blind Randomized Controlled Study of Linoleic Acid Supplementation for 1 Year in Patients With Cystic Fibrosis - Influence on Clinical Status and Metabolism	Cystic Fibrosis	Dietary Supplement: linoleic acid supplementation;Dietary Supplement: oleic acid supplementation	Karolinska Institutet	European Society of Pediatric Gastroenterology, Hepatology and Nutrition	Enrolling by invitation	5 Years	15 Years	All	90	N/A	Italy;Norway;Poland